Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 6/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31202077 | 0.99 | DDB1 (0.56) | DDB1CRBNRAB9ACHRNA7ALDH1A1 | |
| SCHEMBL31202341 | 0.96 | DDB1 (0.59) | DDB1CRBNRAB9ACHRNA7THRB | |
| SCHEMBL31202158 | 0.91 | DDB1 (0.54) | DDB1CRBNRAB9ACHRNA7THRB | |
| SCHEMBL31202004 | 0.91 | DDB1 (0.59) | DDB1CRBNRAB9ACHRNA7ALDH1A1 | |
| SCHEMBL31202198 | 0.89 | DDB1 (0.60) | DDB1CRBNCHRNA7ALDH1A1THRB | |
| SCHEMBL31202101 | 0.89 | DDB1 (0.54) | DDB1CRBNRAB9ACHRNA7ALDH1A1 | |
| SCHEMBL31202537 | 0.89 | DDB1 (0.53) | DDB1CRBNRAB9ACHRNA7THRB | |
| SCHEMBL31202394 | 0.88 | DDB1 (0.53) | DDB1CRBNRAB9ACHRNA7THRB | |
| SCHEMBL31202219 | 0.87 | DDB1 (0.54) | DDB1CRBNRAB9ACHRNA7ALDH1A1 | |
| SCHEMBL24669902 | 0.86 | DDB1 (0.65) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368114-A1 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2024-11-07 | — | — | US | claimed |
| US-20240368114-A1 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | BIOTHERYX INC (US) | 2024-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368114-A1 | INDAZOLES, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS | CSNK1G3, CSNK1A1, CSNK1D | DDB1 3279/4885CRBN 2500/4885RAB9A 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.